Stock IVVD INVIVYD, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Invivyd, Inc.

Equities

IVVD

US00534A1025

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-20 pm EDT 		5-day change 1st Jan Change
2.25 USD -6.25% Intraday chart for Invivyd, Inc. -5.06% -42.89%
May. 09 Transcript : Invivyd, Inc., Q1 2024 Earnings Call, May 09, 2024
May. 09 Invivyd, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Invivyd, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Invivyd, Inc. to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback
Invivyd Names Jeremy Gowler as Interim CEO
Invivyd, Inc. Announces Executive Changes
Invivyd, Inc. Announces CEO Changes
Invivyd's Pemgarda Injection to Prevent Covid Available in US -- Shares Rise After Hours
Invivyd, Inc. Provides Earnings Guidance for the Year 2024
Invivyd, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Sector Update: Health Care Stocks Rise Tuesday Afternoon
Invivyd Clears Significant Hurdle After Pemgarda Authorization, Morgan Stanley Says
Top Premarket Gainers
Invivyd's Covid Treatment for Immunodeficiency Disorders Gets FDA Nod; Shares Up Before Trading Halt
Invivyd, Inc. Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial
Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA? (Formerly VYD222) for Pre-exposure Prophylaxis of COVID-19
Invivyd Submits Request for Emergency Use Authorization to U.S. FDA for VYD222 for the Pre-Exposure Prevention of COVID-19 in Immunocompromised Adults and Adolescents
Invivyd Files Emergency Use Authorization Application for Antibody Candidate Against COVID-19
Sector Update: Health Care Stocks Rise in Late Afternoon
Top Midday Gainers
Invivyd, Inc. Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19
Invivyd, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IVVD Stock
  4. News Invivyd, Inc.
  5. Other languages
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW